Drugs / Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion
Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01701323 | Dec 2012 → May 2018 | acute leukemia of ambiguous lineage | Nohla Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01701323 ↗ |
| Action | Restore | “The infusion of expanded cord blood hematopoietic progenitor cells may be able to replace blood-forming cells that were destroyed by chemotherapy.” NCT01701323 ↗ |
| Modality | Cell therapy | “This cellular therapy may decrease the risk of infection following chemotherapy.” NCT01701323 ↗ |
| Route | Intravenous | “Given IV” NCT01701323 ↗ |